{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:32:44Z","timestamp":1794047564276,"version":"4.8.0"},"reference-count":0,"publisher":"Ferrata Storti Foundation (Haematologica)","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>The clinical paradigm for treatment of classical Hodgkin lymphoma has been transformed by the use of anti-PD-1 therapy, driven by foundational work revealing near-universal 9p24.1 alterations resulting in overexpression of PD-L1 and PD-L2 on Reed-Sternberg cells. Use of PD-1 inhibitors has demonstrated remarkable clinical activity for patients with Hodgkin lymphoma. Anti-PD-1 monotherapy has demonstrated durable remissions in the relapsed\/refractory setting, including a 5-year overall survival of around 70% in clinical trials. Further efforts have evaluated these treatments in various combinations and demonstrated efficacy in both the salvage setting prior to stem cell transplantation (SCT) and the relapsed\/refractory setting after SCT. After such promising results, these agents were moved into the frontline setting with landmark trials such as SWOG S1826, establishing Nivo-AVD (nivolumab, doxorubicin, vinblastine, dacarbazine) as an emerging standard for advanced-stage classical Hodgkin lymphoma. Similarly, Nivo-AVD in the NIVAHL trial demonstrated remarkable efficacy in early stage, unfavorable disease. These agents have a unique mechanism of action that shows promise for patients who would otherwise be chemotherapy-ineligible. The use of these agents is also of interest in the adolescent and young adult populations who would be at risk from long-term side effects of chemotherapy or radiation. This review seeks to examine the safety, efficacy, and feasibility of anti-PD-1 therapy in classical Hodgkin lymphoma.<\/jats:p>","DOI":"10.3324\/haematol.2026.301267","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T07:56:09Z","timestamp":1784793369000},"source":"Crossref","is-referenced-by-count":0,"title":["Safety, feasibility, and efficacy of anti-PD-1 therapy for the treatment of classical Hodgkin lymphoma"],"prefix":"10.3324","author":[{"given":"Jonathan R.","family":"Day","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2026,7,23]]},"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/14315\/80653","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/14315\/80653","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:14:53Z","timestamp":1794046493000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/14315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":0,"URL":"https:\/\/doi.org\/10.3324\/haematol.2026.301267","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,23]]}}}